Upon joining the clinical trial, you will undergo an initial assessment to confirm eligibility. This includes a review of your medical history and a series of tests to ensure you meet the trial’s criteria.

You will be asked to sign an informed consent form, which explains the trial’s purpose, procedures, and potential risks and benefits.

After the initial assessment, you will be randomly assigned to one of two groups: the tisagenlecleucel treatment group or the standard of care group. This process is random to ensure unbiased results.

If assigned to the tisagenlecleucel group, you will receive this treatment through an intravenous infusion. The schedule and dosage will be determined by the study team based on your specific needs.

If assigned to the standard of care group, you will receive medications such as fludarabine phosphate, cyclophosphamide monohydrate, rituximab, and others as per the standard treatment protocol. These may be administered intravenously or orally, depending on the specific medication.

Throughout the trial, regular monitoring will be conducted to assess your response to the treatment. This includes physical exams, blood tests, and imaging studies like CT or PET scans.

You will be required to attend follow-up visits as scheduled by the study team to ensure your safety and to monitor the effectiveness of the treatment.

At the end of the treatment phase, a final assessment will be conducted to evaluate the overall response to the treatment. This will include a comprehensive review of your health status and any changes observed during the trial.

You will receive information about the next steps and any additional follow-up that may be necessary after the trial concludes.